^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD20 underexpression

    i
    Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
    Entrez ID:
    494216
    Related biomarkers:
    Expression
    Others
    6d
    The Expression Levels of CD20 as a Prognostic Value in Feline B-Cell Nasal Lymphoma: A Pilot Study. (PubMed, Animals (Basel))
    Anemia, a common adverse effect in feline nasal lymphoma, did not impact MST. T1 clinical staging and high CD20 expression showed a trend for better MST.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive • CD20 expression • CD20 underexpression
    10ms
    HDAC7 expression improves Diffuse Large B Cell Lymphoma response to rituximab (EACR 2023)
    Cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) treatment regimen has been used for the last decades. As a consequence, the expression of HDAC7 enhanced response to R-CHOP therapy in these cell lines compared to standard CHOP treatment, measured by an induction of apoptosis in DLBCL cells. DLBCL cell lines overexpressing HDAC7 or with high levels of HDAC7 showed an increase in apoptosis when treated with R-CHOP instead of CHOP alone.ConclusionOur data suggest that precise induction of HDAC7 in DLBCL induces CD20 expression, increasing sensitivity of resistant cells to R-CHOP therapy and potentially improving final outcome of DLBCL-diagnosed patients.
    IO biomarker
    |
    HDAC7 (Histone Deacetylase 7)
    |
    CD20 expression • CD20 underexpression
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
    over1year
    Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (ASH 2022)
    Background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is the standard of care for newly diagnosed and untreated diffuse large B-cell lymphoma (DLBCL); however, approximately 30–40% of patients relapse or become refractory...POLARIX (NCT03274492) evaluated a modified regimen substituting polatuzumab vedotin for vincristine (pola-R-CHP), showing a modest improvement in PFS without OS benefit between treatment arms, indicating an unmet clinical need remains...The sensitivity and specificity of minimal residual disease (MRD) for early detection of disease progression is an exploratory endpoint; further MRD parameters may also be investigated. The study is funded by MorphoSys AG and conducted with the scientific support of members of the Fondazione Italiana Linfomi and the German Lymphoma Alliance.
    Clinical • P3 data
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 expression • CD20 underexpression
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq)
    over2years
    Expression of CD20 Affects Early MRD Response to Rituximab in Adult B Cell Precursor Lymphoblastic Leukemia of the GMALL 08/2013 Trial (ASH 2021)
    Moreover, CD20 expression might differ between blood (pb) and bone marrow (bm) and varies under prednisone during early treatment...Methods Comparative immunophenotypic quantification of CD20 expression in 207 B-ALL pts was performed at diagnosis (pb d0 and/or bm d0) and/or (a/o) after a 5-day dexamethasone- and cyclophosphamide-containing prephase (pb d6) under EuroFlow standardized procedures...Accordingly, R seems to improve the early MRD response predominantly in pts with higher CD20 expression. Supported by DJCLS
    Clinical
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 expression • CD20 underexpression
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone